Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Docetaxel + RhFzd7|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Docetaxel||Taxotere||RP56976||Antimicrotubule Agent 13||Taxotere (docetaxel) binds to tubulin, inhibiting microtubule disassembly and preventing cell division (PMID: 32496783, PMID: 32366558).|
|RhFzd7||WNT Inhibitor 10||RhFzd7 is peptide fragment that consists of the extracellular domain of Frizzled 7 (Fzd7), which binds to Wnt3a and competes with binding to Fzd7, potentially resulting in apoptosis and inhibition of cellular invasion and proliferation (PMID: 30096373).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||triple-receptor negative breast cancer||not applicable||Docetaxel + RhFzd7||Preclinical - Cell line xenograft||Actionable||In a preclinical study, treatment with the combination of RhFzd7 and Taxotere (docetaxel) resulted in increased inhibition of proliferation and decreased tumor growth and neovascularization compared to either agent alone in cell line xenograft models of triple-negative breast cancer (PMID: 30096373).||30096373|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|